This is the second in a series of three educational webinars outlining what regulatory actions are required as a result of changes under the EU MDR, with a focus on manufacturer evidence and variations to the ARTG, and what the Therapeutic Goods Administration (TGA) is doing to streamline the transition process.
Presenters
Dr Xin-Lin Goh, Director, Devices Applications, TGA
